Abstracts tagged "pain and psoriatic arthritis"

Abstract Number: 2561 • 2018 ACR/ARHP Annual Meeting
Rapid and Sustained Improvements in Patient-Reported Signs and Symptoms with Ixekizumab in Biologic-Naive and TNF-Inadequate Responder Patients with Psoriatic Arthritis
Ana-Maria Orbai¹, Dafna D Gladman², Julie Birt³, Amanda M. Gellett³, Chen-Yen Lin³ and Tore Kvien⁴, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Toronto, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Ixekizumab (IXE), a high-affinity mAb that selectively targets IL-17A, has shown improvements up to Week (Wk) 24 across several domains of PsA (including ACR20)…
Abstract Number: 58 • 2014 ACR/ARHP Annual Meeting
What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis
Sandra Tälli¹, Adrien Etcheto², Bruno Fautrel³, Andra Balanescu⁴, Jürgen Braun⁴, Juan D. Cañete⁵, Kurt de Vlam⁴, Maarten de Wit⁴, Turid Heiberg⁴, Philip S. Helliwell⁴, Umut Kalyoncu⁴, Uta Kiltz⁶, Mara Maccarone⁴, Dora Niedermayer⁴, Kati Otsa⁴, Rossana Scrivo⁴, Josef Smolen⁴, Tanja Alexandra Stamm⁴, Douglas J. Veale⁷, Tore K. Kvien⁴ and Laure Gossec³, ¹Rheumatology, GRC UPMC Paris 06 University, Pitie-Salpétriere hospital, Paris, France, ²Cochin Hospital, Paris Descartes University, Paris, France, ³Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁴PsAID taskforce, EULAR, Zurich, Switzerland, ⁵Rheumatology, Hospital Clinic, Barcelona, Spain, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Translational Rheumatology Research Group, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose Patient global assessment (PGA) is one of the most widely used patient reported outcomes (PROs) in psoriatic arthritis (PsA). PGA should reflect the global…
Abstract Number: 557 • 2012 ACR/ARHP Annual Meeting
Effect of Certolizumab Pegol On the Multiple Facets of Psoriatic Arthritis As Reported by Patients: 24 Week Patient Reported Outcome Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Dafna D. Gladman¹, Roy Fleischmann², Geoffroy Coteur³, Franz Woltering⁴ and Philip J. Mease⁵, ¹Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Monheim, Germany, ⁵Seattle Rheumatology Associates, Seattle, WA
Background/Purpose: RAPID-PsA (NCT01087788) reports efficacy and safety of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in psoriatic arthritis (PsA).1 The effect of different imputation methodologies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].